Home' Australian Pharmacist : June 2011 Contents Vol. 30 -- June #06
Continuing Professional Development
Submit your answers online at www.psa.org.au and receive automatic feedback
convenient diagnostic methods
• Being the most accessible health
care professionals and often the
first point of call for patients,
there is scope for community
pharmacists to play a role in the
area of screening and identification
of undiagnosed OSA.
• Enquiries about snoring, apnoea-like
symptoms and daytime sleepiness
should form part of the regular
counselling process of pharmacists.
1. Smith IE, Quinnell TG. Pharmacotherapies for
Obstructive Sleep Apnoea. Pharmacotherapy for
Obstructive Sleep Apnoea. 2004; 4:1385--99.
2. Pharmacy 777. What is sleep apnoea? [online].
[Accessed 17 Mar 2011]. At: www.pharmacy777.com.
3. American Academy of Sleep Medicine. International
Classification of Sleep Disorders: Diagnostic and
Coding Manual [accessed 12 Nov 2009. 2001 :39--43.
4. Veasy SC. Molecular and physiologic basis of
obstructive sleep apnea. Clinics in Chest Medicine.
5. Kee K, Naughton MT. Sleep Apnoea -- A general
practice approach. Aust Fam Physician. 2009; 38:284--8.
6. Otake K, Delaive K, Walld R, et al. Cardiovascular
medication use in patients with undiagnosed
obstructive sleep apnoea. Thorax. 2002; 57:417--22.
7. Gyllenhaal C, Merritt S, Peterson S, et al. Efficacy and
safety of herbal stimulants and sedatives in sleep
disorders. Sleep Medicines Reviews. 2000; 4:229--51.
8. Smith SS, Dingwall K, Jorgenson G, et al. Associations
between the use of common medications and sleep
architecture in patients with untreated obstructive
sleep apnea. Journal of Clinical Sleep Medicine. 2005;
9. Smith R, Ronald J, Delaive K, et al. What are
obstructive sleep apnea patients being treated for prior
to this diagnosis? Chest. 2002; 121:164--72.
10. Scanlan MF, Roebuck T, Little PJ, et al. Effect of
moderate alcohol upon obstructive sleep apnoea. Eur
Respir J. 2000; 16:909--13.
11. Chai-Coetzer CL, Antic NA, Rowland LS. A simplified
model of screening questionnaire and home monitoring
for obstructive sleep apnoea in primary care. Thorax.
12. Netzer N, Stoohs R, Netzer C. Using the Berlin
Questionnaire to identify patients at risk for the sleep
apnea syndrome. Ann Intern Med. 1999; 131:485--536.
13. Johns M. A new method for measuring daytime
sleepiness: the Epworth sleepiness scale. Sleep. 1991;
14. Simon R, Greenberg D, Aminoff M. Clinical Neurology.
Ch. 27: Sleep Disorders. London: Lange Medical/
McGraw Hill; 2009.
15. Whitelaw WA, Brang RF, Flemons WW. Clinical
usefulnes of home oximetry compared with
polysomnography for assessment of sleep apnoea. Am
J Respir Crit Care Med. 2004; 171:188--93.
16. White D, Gibb T, Wall J, et al. Assessment of accuracy
and analysis time of a novel device to monitor sleep
and breathing in the home. Sleep. 1995; 18:115--26.
17. Whitehead D, Taket A, Smith P. Action Research in
health promotion. Health Educ J. 2003; 62:5--22.
18. Sanchez AI, Martinez P, Miro E, et al. CPAP and
behavioral therapies in patients with obstructive sleep
apnea: Effects on daytime sleepiness, mood, and
cognitive function. Sleep Medicine Reviews. 2009;
19. Prakash KC, Nissen LM, Kyle G, et al. Nonprescription
treatments for snoring and insomnia: is there any
evidence to support their use? In: Proceedings of the
Australasian Pharmaceutical Science Association
Annual Conference, 2010; Brisbane.
20. Meoli AL, Rosen CL, Kristo D, et al. Nonprescription
treatments of snoring or obstructive sleep apnea: An
evaluation of products with limited scientific evidence.
Sleep. 2003; 26:619--24.
21. Hersberger KE, Renggli VP, Nirkko AC, et al. Screening
for sleep disorders in community pharmacies --
evaluation of a campaign in Switzerland. Journal of
Clinical Pharmacy and Therapeutics. 2006; 31:35--41.
22. Schwegler K, Klaghofer R, Nirkko AC, et al. Sleep
and wakefulness disturbances in Swiss pharmacy
customers. Swiss Med Weekly. 2006; 136:149--54.
23. Tran A, Fuller JM, Wong KK, et al. The development
of a sleep disorder screening program in Australian
community pharmacies. Pharmacy World and Science.
1. Which of the following are
common risk factors for
a) Hypertension, cardiovascular
b) Osteoarthritis, gallbladder disease,
c) Pain, hypertension, dyslipidaemia,
d) Cirrhosis of the liver, osteoarthritis,
gallbladder disease, non-insulin
2. The MOST COMMON
symptoms of OSA in
a) loud snoring, sweating, chest pain,
b) loud snoring, excessive daytime
sleepiness, dry mouth, nighttime
c) morning headaches, loud snoring,
swelling of legs, increased
d) excessive daytime sleepiness,
depression, frequent urination,
3. Which of the following
individuals is MOST at risk of
a) Neil -- smoker, BMI of 34, avoids
alcohol, age 35.
b) Heidi -- avoids alcohol, avoids
smoking, BMI of 33, age 42.
c) Chris -- alcoholic, BMI of 34,
snores, hypertension, age 35.
d) Gina -- drinks alcohol, BMI of 22,
sleeps on back, age 35.
4. Which of the following
statements is INCORRECT?
a) Laboratory attended PSG is a
labour-intensive process and can
b) Home PSG has the disadvantage
of high failure rates due to
incorrect set up and use.
c) Home PSG is a much more
convenient and comfortable option
A score of 4 out of 5 attracts 1 CPD credit.
d) Portable sleep apnoea monitor
devices have always been the 'gold
standard' for diagnosis of OSA.
5. The most commonly chosen
management option for OSA
a) a continuous positive airway
pressure machine that creates
airflow through a nasal mask.
b) a mandibular advancement device
c) bariatric surgery for obese
Links Archive July 2011 May 2011 Navigation Previous Page Next Page